Category Archives: Stem Cell Therapy

Business Wire

Eastern Bank Charitable Foundation (EBCF), the philanthropic arm of Eastern Bank, today announced its annual community support is expected to exceed $22 million, an all-time high, by the end of 2020. This includes an additional $3 million philanthropic investment to help address the impact of COVID-19 in the communities Eastern Bank serves. Added to the $8 million provided earlier this year, EBCFs total for COVID-19 philanthropic relief for the year now stands at $11 million. EBCFs 2020 philanthropy also includes continued grassroots community support in a range of areas led by nonprofit organizations in the communities where Eastern Bank operates, as well as further philanthropic support to address economic inclusion and mobility, particularly at the intersections of equity for businesses of color, early childhood development, safe and affordable housing, and workforce development, all areas experiencing growing need during the pandemic.

Read the rest here:
Autologous Stem Cell & Non-Stem Cell Based Therapies Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19 - Yahoo...

The treatment landscape of lymphoid malignancies space is rich with available immunotherapy agents, said Joshua Brody, MD. However, the field continues to push toward improving response rates by refining established modalities, such as CAR T-cell therapy and checkpoint inhibitors, as well as introducing novel modalities.

During the5th AnnualInternational Congress on Immunotherapies in Cancer, a program run by Physicians Education Resource (PER), Brody, an assistant professor of medicine, hematology, and medical oncology and director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, gave a presentation on established and upcoming immunotherapies in the lymphoid malignancy pipeline.

We are somewhat lucky, and maybe a bit spoiled in lymphoid malignancies, such as lymphomas and some B-cell malignancies, to have [seen] a huge amount of progress [with immunotherapy], said Brody.

However, lymphoid malignancies are highly heterogeneous. As such, not all patients are able to derive responses from the same therapy, Brody explained.

CAR T-cell therapy represents a significant advance in the treatment paradigms of several hematologic malignancies, including lymphoid malignancies, said Brody.

The results [of CAR T-cell therapy treatment] for patients with aggressive B-cell lymphomas have been amazing, Brody said. [CAR T-cell therapy] has shown higher response rates [in this space] than any other immunotherapy for any type of cancer; response rates are above 80%. Many of those [responses] are long lasting, complete remissions [CRs].

Notably, it is thought that patients who remain in CR for at least 6 to 12 months after CAR T-cell therapy infusion are likely cured of their lymphoma, Brody said. For example, it is likely that around 35% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) who receive CAR T-cell therapy are effectively cured.

Third-line [DLBCL], the most common type of lymphoma, [was thought to be] an incurable disease setting, said Brody. We [thought we could] cure people in the first- or second-line setting, but not beyond. Im not sure how we define a miracle, but it seems miraculous to me to change the incurable to partly curable.

Now, ongoing research efforts are attempting to refine CAR T-cell therapies to enhance responses and expand the utility of the modality to other hematologic malignancies beyond DLBCL, acute leukemia, and mantle cell lymphoma, explained Brody. For example, developing armored CAR T cells and fourth-generation CAR T cellsT cellsredirected for antigenunrestricted cytokineinitiated killingmay allow for improved delivery of cytotoxic payloads to liquid as well as solid tumors.

Additionally, novel CAR T-cell therapies may overcome some of the ongoing challenges observed with current, autologous products, such as toxicity, accessibility, and feasibility. For example, utilizing an allogeneic approach to CAR T-cell therapy may allow for an off-the-shelf option that could alleviate the risk of cytokine release syndrome and neurotoxicity.

Beyond CAR T-cell therapy, bispecific monoclonal antibodies, such as the investigational CD20/CD3-directed REGN1979 agent, could potentially be used in patients who progress after CAR T-cell therapy. Findings from a phase 1 trial (NCT02290951) demonstrated high objective response rates and CR rates among patients with heavily pretreated, relapsed/refractory NHL who were treated with REGN1979.1

Although the toxicity challenges of CAR T-cell therapies are likely not going to be solved with bispecific antibodies, the novel agents may offer an alternative option that can decrease the risk of adverse effects.

At least with [bispecific antibodies], we can tweak and optimize [dosing] a bit, explained Brody. CAR T-cell therapy is usually a one-shot therapy, [whereas] bispecifics can be given in low, medium, or high doses. We can up-titrate the therapy to try to minimize or avoid some of these toxicities.

Additionally, bispecific antibodies are potentially able to avoid antigen escape, which is a common concern with CD19/CD20-directed CAR T-cell therapies, Brody explained.

PD-1/PD-L1 inhibitors have transformed the treatment landscape in melanoma, lung cancer, renal cell carcinoma, and bladder cancer. However, Hodgkin lymphoma is the most responsive disease to antiPD-1 agents because chromosomal amplifications or translocations are hardwired to overexpress PD-1, Brody said.

As such, responses with checkpoint inhibitors, such as nivolumab (Opdivo), are seen in around 70% of patients with Hodgkin lymphoma who progress following autologous stem cell transplant.2

The introduction of checkpoint inhibitors to this space has been particularly encouraging for younger patients who fail curative-intent chemotherapy and who, historically, had dismal prognoses.

Currently, ongoing efforts are attempting to bring PD-1 inhibitors to the second-line setting and, potentially, up-front settings in combination with chemotherapy.

Although it is true that hot tumors are more likely to respond to immunotherapy compared with cold tumors, it is not the only factor that contributes to whether a tumor will respond. As such, alternative methods of improving immune response in patients with lymphoid malignancies are being evaluated.

For example, one investigational method is to utilize radiotherapy or other means to mobilize dendritic cells loaded with tumor antigens to antigen-presenting cells. Ultimately, this compound could serve as a therapeutic anti-cancer vaccine to deliver the antigens, as well as costimulatory signals, to the cancer cells.

As such, an ongoing trial (NCT03789097) led by Brody is currently testing an in situ vaccine combining radiation therapy, the immune cell growth factor Flt3L/CDX-301, the immune-cell activating factor Poly-ICLC, and pembrolizumab (Keytruda).3 Initial findings from the study have yielded encouraging results, according to Brody.

In situ vaccines such as this may be able to cross prime T cells and increase the effectiveness of immunotherapy for patients, Brody concluded.

Read more:
Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies - OncLive

NK Cell Therapy and Stem Cell Therapy Marketresearch report is the new statistical data source added byA2Z Market Research.

NK Cell Therapy and Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

NK Cell Therapy and Stem Cell Therapy Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=325609

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

Chipscreen Biosciences, Innate Pharma SA, Osiris Therapeutics, Chiesi Pharmaceuticals, Molmed, JCR Pharmaceutical, Altor BioScience Corporation, Affimed NV, Takeda Pharmaceutical, Pharmicell, Medi-post, NuVasive, Anterogen.

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global NK Cell Therapy and Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the NK Cell Therapy and Stem Cell Therapy markets trajectory between forecast periods.

Global NK Cell Therapy and Stem Cell Therapy Market Segmentation:

Market Segmentation: By Type

NK Cell TherapyStem Cell Therapy

Market Segmentation: By Application

Hospital & clinicsRegenerative medicine centersDiagnostic centersResearch institutesOthers

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=325609

Regions Covered in the Global NK Cell Therapy and Stem Cell Therapy Market Report 2021:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global NK Cell Therapy and Stem Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the NK Cell Therapy and Stem Cell Therapy market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the NK Cell Therapy and Stem Cell Therapy market.

Table of Contents

Global NK Cell Therapy and Stem Cell Therapy Market Research Report 2021 2027

Chapter 1 NK Cell Therapy and Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global NK Cell Therapy and Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=325609

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Follow this link:
Comprehensive Report on NK Cell Therapy and Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | Chipscreen...

New Jersey, United States,- The report, titled Stem Cell Therapy Market Size By Types, Applications, Segmentation, and Growth Global Analysis and Forecast to 2019-2027 first introduced the fundamentals of Stem Cell Therapy: definitions, classifications, applications and market overview; Product specifications; Production method; Cost Structures, Raw Materials, etc. The report takes into account the impact of the novel COVID-19 pandemic on the Stem Cell Therapy market and also provides an assessment of the market definition as well as the identification of the top key manufacturers which are analyzed in-depth as opposed to the competitive landscape. In terms of Price, Sales, Capacity, Import, Export, Stem Cell Therapy Market Size, Consumption, Gross, Gross Margin, Sales, and Market Share. Quantitative analysis of the Stem Cell Therapy industry from 2019 to 2027 by region, type, application, and consumption rating by region.

Impact of COVID-19 on Stem Cell Therapy Market: The Coronavirus Recession is an economic recession that will hit the global economy in 2020 due to the COVID-19 pandemic. The pandemic could affect three main aspects of the global economy: manufacturing, supply chain, business and financial markets. The report offers a full version of the Stem Cell Therapy Market, outlining the impact of COVID-19 and the changes expected on the future prospects of the industry, taking into account political, economic, social, and technological parameters.

Request Sample Copy of this Report @ Stem Cell Therapy Market Size

In market segmentation by manufacturers, the report covers the following companies-

How to overcome obstacles for the septennial 2020-2027 using the Global Stem Cell Therapy market report?

Presently, going to the main part-outside elements. Porters five powers are the main components to be thought of while moving into new business markets. The customers get the opportunity to use the approaches to plan the field-tested strategies without any preparation for the impending monetary years.

We have faith in our services and the data we share with our esteemed customers. In this way, we have done long periods of examination and top to bottom investigation of the Global Stem Cell Therapy market to give out profound bits of knowledge about the Global Stem Cell Therapy market. Along these lines, the customers are enabled with the instruments of data (as far as raw numbers are concerned).

The graphs, diagrams and infographics are utilized to speak out about the market drifts that have formed the market. Past patterns uncover the market turbulences and the final results on the markets. Then again, the investigation of latest things uncovered the ways, the organizations must take for shaping themselves to line up with the market.

Stem Cell Therapy Market: Regional analysis includes:

?Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)?Europe(Turkey, Germany, Russia UK, Italy, France, etc.)?North America(the United States, Mexico, and Canada.)?South America(Brazil etc.)?The Middle East and Africa(GCC Countries and Egypt.)

The report includes Competitors Landscape:

? Major trends and growth projections by region and country? Key winning strategies followed by the competitors? Who are the key competitors in this industry?? What shall be the potential of this industry over the forecast tenure?? What are the factors propelling the demand for the Stem Cell Therapy Industry?? What are the opportunities that shall aid in the significant proliferation of market growth?? What are the regional and country wise regulations that shall either hamper or boost the demand for Stem Cell Therapy Industry?? How has the covid-19 impacted the growth of the market?? Has the supply chain disruption caused changes in the entire value chain?

The report also covers the trade scenario,Porters Analysis,PESTLE analysis, value chain analysis, company market share, segmental analysis.

About us:

Market Research Blogs is a leading Global Research and Consulting firm servicing over 5000+ customers. Market Research Blogs provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Get More Market Research Report Click @ Market Research Blogs

See the original post here:
Stem Cell Therapy Market Size 2020 by Top Key Players, Global Trend, Types, Applications, Regional Demand, Forecast to 2027 - LionLowdown

Animal Stem Cell Therapy Marketresearch report is the new statistical data source added byA2Z Market Research.

Animal Stem Cell Therapy Market is growing at a High CAGR during the forecast period 2021-2027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Animal Stem Cell Therapy Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=286567

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report are:

ANIMAL CELL THERAPIES, Celavet, Animacel, VETSTEM BIOPHARMA, Cell Therapy Sciences, Magellan Stem Cells, Cells Power Japan, Animal Care Stem, Aratana Therapeutics, VetCell Therapeutics, MediVet Biologic, U.S. Stem Cell, J-ARM

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Animal Stem Cell Therapy market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Animal Stem Cell Therapy markets trajectory between forecast periods.

Global Animal Stem Cell Therapy Market Segmentation:

Market Segmentation: By Type

DogsHorsesOthers

Market Segmentation: By Application

Veterinary HospitalsResearch Organizations

Get up to 30% Discount on this Premium Report @:

https://www.a2zmarketresearch.com/discount?reportId=286567

Regions Covered in the Global Animal Stem Cell Therapy Market Report 2021:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Animal Stem Cell Therapy Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

The report provides insights on the following pointers:

Market Penetration:Comprehensive information on the product portfolios of the top players in the Animal Stem Cell Therapy market.

Product Development/Innovation:Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development:Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification:Exhaustive information about new products, untapped geographies, recent developments, and investments in the Animal Stem Cell Therapy market.

Table of Contents

Global Animal Stem Cell Therapy Market Research Report 2021 2027

Chapter 1 Animal Stem Cell Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Animal Stem Cell Therapy Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=286567

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

See more here:
Comprehensive Report on Animal Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | ANIMAL CELL THERAPIES,...

Patient dosing has finished in a Phase 2 clinical trial testingNurOwn, BrainStorm Cell Therapeutics investigational cell-based therapy for people with progressive multiple sclerosis (MS), the company announced.

The trials top-line results are expected by April.

Now that all dosing of the NurOwn Phase 2 progressive MS clinical trial is complete, we will shift our focus to completing all remaining patient clinical trial assessments and biomarker analyses, Ralph Kern, MD, BrainStorms president and chief medical officer, said in a press release.

We look forward to generating clinical trial top line results by the end of the first quarter 2021 and to advancing this promising treatment option based on a thorough analysis of the clinical trial outcomes, Kern added.

Stacy Lindborg, PhD, BrainStorms executive vice president and head of global clinical research, noted that the full study data will be shared with the MS scientific community at upcoming conferences and in subsequent publications to help advance understanding of progressive MS and the potential benefits of NurOwn as a treatment.

NurOwn involves collecting mesenchymal stem cells (MSCs) from a patients own bone marrow, and expanding and maturating them into cells that produce high levels of neurotrophic factors (NTF) molecules that promote nerve cell growth and survival. MSCs are stem cells that can generate a variety of other cell types.

The mature cells called MSC-NTF cells are then injected into the patients spinal canal to promote and support nerve cell repair. Using a patients own cells minimizes the risk of an immune reaction, as might occur with cells from a donor.

In MS, NurOwn is believed to promote the repair of myelin the protective sheath around nerve fibers that is lost in MS lessen the likelihood of further damage, and potentially slow disease progression.

A previous preclinical study suggested that NurOwn may also be able to suppress the damaging immune responses that contribute to MS progression, by promoting a cellular and molecular shift toward an anti-inflammatory state.

The open-label Phase 2 trial (NCT03799718) is evaluating NurOwns safety and effectiveness in 20 adults, ages 18 to 65, with either primary progressive MS or secondary progressive MS. Patient enrollment started in March 2019, and the trial is taking place at five U.S. sites.

Participants received a total of three injections of NurOwn, directly into the spinal canal, over a 16-week period (about four months), and will now be followed for 12 weeks (about three months) for safety and effectiveness measurements.

The studys main goal is to assess the safety of the procedure. Effectiveness goals include changes in patients walking abilities or finger dexterity, as well as in the levels of neurotrophic and immunomodulatory biomarkers in their cerebrospinal fluid (the liquid that bathes the brain and the spinal cord).

Completed dosing of the Phase 2 progressive MS clinical trial is a major milestone for BrainStorm as we advance our goal to develop the NurOwn platform technology in neurodegenerative diseases, saidChaim Lebovits, BrainStorms CEO.

We are very thankful for the dedicated efforts of the investigators and their teams and to the patients who participated in this important clinical trial. Through their combined efforts, we hope to bring a promising therapeutic option to those affected by progressive MS, Lebovits added.

BrainStorm also is evaluating NurOwn as a potential therapy for other neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinsons disease, and Huntingtons disease, as well as for autism spectrum disorder.

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

Total Posts: 1,053

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Read the original:
Dosing Finishes in Trial of NurOwn Cell Therapy for Progressive MS - Multiple Sclerosis News Today